Prothena Corporation plc Logo

Email this page: News Release

Prothena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases

For security reasons, registration is required before you can use this feature.
* Indicates required field